MedicX Fund Interim Results: Strong Revenue, EBITDA Growth
Edison | Dec 23, 2012 11:01PM ET
MedicX (MXF.L) accelerated its portfolio growth in FY12 and a £134m investment pipeline puts it in a position to maintain momentum this year. Dividend cover will improve, as EPS-enhancing investment flows to the bottom line, particularly as £66m of year-end cash is absorbed by acquisitions. Portfolio growth adds to profits as the 5.8-6.0% initial yield available on acquisitions exceeds the group’s all-in cost of borrowing (4.45%), incremental investment/property management fees and other costs.
FY12 results: Strong revenue and EBITDA growth
A 33% increase in rental income and c 40% in EBITDA reflected portfolio growth. MedicX committed £146.5m to new assets in FY12 at a 6.03% cash yield, grew its portfolio to £394.8m and annualised rent roll to £24.8m (FY11: £15.2m). There was a £134m FY12 year-end pipeline of investment opportunities. Aggregate group loan-to-value was 70% at the year end (FY11: 47%); total debt £244m at a weighted average 4.45% (FY11: 4.82%) funding cost and 16.8 year (FY11: 22.4 years) unexpired term.
Financials: Funds in place for further acquisitions
MedicX raised £48.7m (net) in new equity in FY12; 67.8m shares at 73.3p/share, above NAV/share. It also drew down £81.2m of debt facilities £31.2m (Deutsche Postbank at 2.75% pa fixed until expiry in April 2015), £50m (Aviva at a 4.37% fixed for 20 years to February 2032) and assumed £80.2m of debt via two corporate acquisitions. Of the latter, £16.4m has been repaid and the interest rate on the £63.8m balance reset post the year end to an average 4.45% pa fixed for a 12.4-year unexpired term. Debt drawn down in anticipation of further investment is included in £66m of year-end cash.
Valuation: Backed by 7.7% prospective yield
Yield is the key to the valuation; our forecasts put the shares on prospective 7.7% and 7.8% yields. These are not covered by cash earnings and although MedicX has never committed to this being the case, continued portfolio growth will narrow the gap. We assume £120m of portfolio additions this year, £100m in FY14, funded by £50m of new equity in each year at the current price, and debt at c 4.5% pa. That level of acquisitions should broadly improve underlying dividend cover by c 2-3% in a full year; we expect c 59% and 63% in FY13 and FY14 respectively, c 65% and 69% adjusted for a 9% scrip take-up (11.6% and 8% for last two quarters). MedicX’s own calculation shows that if all assets acquired were complete and held for a full year, the FY12 dividend would have been 68% covered, or 108% including revaluation gains.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.